{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:49:17Z","timestamp":1769633357039,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cardiacep.theclinics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiac Electrophysiology Clinics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ccep.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:18:10Z","timestamp":1763648290000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiarrhythmic Drug Therapy for Acute Management of Atrial Fibrillation and Atrial Flutter"],"prefix":"10.1016","volume":"18","author":[{"given":"Mohammadali","family":"Habibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneet","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ccep.2025.10.003_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009024","article-title":"Emergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from 2007 to 2014","volume":"7","author":"Rozen","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"10.1016\/j.ccep.2025.10.003_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13164883","article-title":"Nationwide trends in hospitalizations for atrial fibrillation and flutter in the United States before and during the outbreak of the COVID-19 pandemic","volume":"13","author":"Daoudi","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0735-1097(97)00534-2","article-title":"Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm","volume":"31","author":"Danias","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ccep.2025.10.003_bib4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus strict rate control in patients with atrial fibrillation","volume":"362","author":"Van Gelder","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ccep.2025.10.003_bib5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.ccep.2025.10.003_bib7","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ccep.2025.10.003_bib8","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1161\/CIRCULATIONAHA.111.019919","article-title":"Rate control in atrial fibrillation","volume":"124","author":"Heist","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ccep.2025.10.003_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.ajem.2020.06.034","article-title":"Hemodynamic comparison of intravenous push diltiazem versus metoprolol for atrial fibrillation rate control","volume":"38","author":"Nicholson","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0196-0644(97)70319-6","article-title":"Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin","volume":"29","author":"Schreck","year":"1997","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.ccep.2025.10.003_bib11","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/CCM.0b013e3181a02f56","article-title":"Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation","volume":"37","author":"Siu","year":"2009","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ccep.2025.10.003_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2046-4053-2-7","article-title":"Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design","volume":"2","author":"Kotecha","year":"2013","journal-title":"Syst Rev"},{"issue":"46","key":"10.1016\/j.ccep.2025.10.003_bib14","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ccep.2025.10.003_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1253\/circrep.CR-19-0076","article-title":"Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction","volume":"1","author":"Iwahashi","year":"2019","journal-title":"Circ Rep"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jemermed.2018.12.010","article-title":"Esmolol compared with amiodarone in the treatment of Recent-Onset Atrial Fibrillation (RAF): an emergency medicine external validity study","volume":"56","author":"Milojevic","year":"2019","journal-title":"J Emerg Med"},{"issue":"13","key":"10.1016\/j.ccep.2025.10.003_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0002-9149(89)90141-0","article-title":"Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter","volume":"63","author":"Platia","year":"1989","journal-title":"Am J Cardiol"},{"issue":"6752","key":"10.1016\/j.ccep.2025.10.003_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.301.6752.587","article-title":"Atenolol in essential hypertension during pregnancy","volume":"301","author":"Butters","year":"1990","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib19","first-page":"49","article-title":"Digoxin and risk of death in adults with atrial fibrillation","volume":"8","author":"Freeman","year":"2015","journal-title":"Circulation"},{"issue":"28","key":"10.1016\/j.ccep.2025.10.003_bib20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/eurheartj\/ehv143","article-title":"Digoxin-associated mortality: a systematic review and meta-analysis of the literature","volume":"36","author":"Vamos","year":"2015","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccep.2025.10.003_bib21","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.jacc.2003.07.020","article-title":"Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?","volume":"42","author":"Khand","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ccep.2025.10.003_bib22","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA, J Am Med Assoc"},{"issue":"24","key":"10.1016\/j.ccep.2025.10.003_bib23","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2165\/00003495-200464240-00003","article-title":"Pharmacological cardioversion of atrial fibrillation: current management and treatment options","volume":"64","author":"Boriani","year":"2004","journal-title":"Drugs"},{"issue":"6a","key":"10.1016\/j.ccep.2025.10.003_bib24","doi-asserted-by":"crossref","first-page":"15d","DOI":"10.1016\/S0002-9149(02)03375-1","article-title":"Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials","volume":"91","author":"Naccarelli","year":"2003","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ccep.2025.10.003_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/eurheartj\/14.8.1127","article-title":"Comparison of flecainide and procainamide in cardioversion of atrial fibrillation","volume":"14","author":"Madrid","year":"1993","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1007714203984","article-title":"Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion","volume":"12","author":"Kochiadakis","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10.1016\/j.ccep.2025.10.003_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.amjcard.2007.01.059","article-title":"A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation","volume":"99","author":"Kochiadakis","year":"2007","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2006.07.017","article-title":"Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter","volume":"118","author":"Kafkas","year":"2007","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.ccep.2025.10.003_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(98)00078-3","article-title":"Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation","volume":"31","author":"Volgman","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccep.2025.10.003_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9149(99)80137-4","article-title":"Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol-digoxin-quinidine trial)","volume":"76","author":"Halinen","year":"1995","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/oxfordjournals.eurheartj.a062498","article-title":"Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study","volume":"9","author":"Karlson","year":"1988","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ccep.2025.10.003_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF02125745","article-title":"Clinical electrophysiologic effects of flecainide acetate","volume":"1","author":"Mehta","year":"1988","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"10.1016\/j.ccep.2025.10.003_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0002-9149(89)90253-1","article-title":"Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm","volume":"63","author":"Suttorp","year":"1989","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2025.10.003_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0002-9149(91)90435-N","article-title":"Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide","volume":"67","author":"Donovan","year":"1991","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2025.10.003_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0002-9149(98)00412-3","article-title":"Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 investigators. The propafenone in atrial fibrillation Italian trial","volume":"82","author":"Bianconi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2025.10.003_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/clc.4960190515","article-title":"Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. paroxysmal atrial fibrillation italian trial (PAFIT)-2 investigators","volume":"19","author":"Fresco","year":"1996","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.ccep.2025.10.003_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0002-9149(94)90915-6","article-title":"Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide","volume":"74","author":"Capucci","year":"1994","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9149(92)91392-H","article-title":"Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension","volume":"70","author":"Capucci","year":"1992","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.ccep.2025.10.003_bib39","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ehj.2004.04.030","article-title":"Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset","volume":"25","author":"Reisinger","year":"2004","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ccep.2025.10.003_bib40","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0002-9149(98)00223-9","article-title":"Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation","volume":"81","author":"Reisinger","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ccep.2025.10.003_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-5273(98)00363-5","article-title":"Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study","volume":"68","author":"Capucci","year":"1999","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ccep.2025.10.003_bib42","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1540-8159.2009.02441.x","article-title":"Cardioversion for atrial fibrillation: treatment options and advances","volume":"32","author":"Reiffel","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"issue":"23","key":"10.1016\/j.ccep.2025.10.003_bib43","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ccep.2025.10.003_bib44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jacep.2022.07.010","article-title":"Safety of pill-in-the-pocket class 1C antiarrhythmic drugs for atrial fibrillation","volume":"8","author":"Markman","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccep.2025.10.003_bib45","first-page":"1021","article-title":"Orally inhaled flecainide for conversion of atrial fibrillation to sinus rhythm","volume":"10","author":"Ruskin","year":"2024","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"11 Pt 2","key":"10.1016\/j.ccep.2025.10.003_bib46","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1111\/j.1540-8159.1998.tb01204.x","article-title":"Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study","volume":"21","author":"Kochiadakis","year":"1998","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.ccep.2025.10.003_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10557-020-07127-1","article-title":"Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysis","volume":"35","author":"Tsiachris","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2007.02.024","article-title":"Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration","volume":"121","author":"Xanthos","year":"2007","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.ccep.2025.10.003_bib49","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/oxfordjournals.eurheartj.a060401","article-title":"A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachyarrhythmia","volume":"15","author":"Andrivet","year":"1994","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1996.00440010061008","article-title":"The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation","volume":"156","author":"Kerin","year":"1996","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ccep.2025.10.003_bib51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.CIR.97.5.493","article-title":"Ibutilide","volume":"97","author":"Murray","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccep.2025.10.003_bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0002-9149(97)00395-0","article-title":"Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function","volume":"80","author":"Stambler","year":"1997","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ccep.2025.10.003_bib53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/hrt.79.6.568","article-title":"Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide\/Sotalol Comparator Study Group","volume":"79","author":"Vos","year":"1998","journal-title":"Heart"},{"issue":"16","key":"10.1016\/j.ccep.2025.10.003_bib54","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/hc4101.097538","article-title":"Electrophysiological effects of ibutilide in patients with accessory pathways","volume":"104","author":"Glatter","year":"2001","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ccep.2025.10.003_bib55","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJM199906173402401","article-title":"Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment","volume":"340","author":"Oral","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.104.3.292","article-title":"Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy","volume":"104","author":"Pedersen","year":"2001","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccep.2025.10.003_bib57","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1540-8159.2007.00902.x","article-title":"Acute conversion of persistent atrial fibrillation during dofetilide initiation","volume":"30","author":"Cotiga","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"issue":"19","key":"10.1016\/j.ccep.2025.10.003_bib58","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study","volume":"102","author":"Singh","year":"2000","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ccep.2025.10.003_bib59","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1053\/euhj.1999.2049","article-title":"Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure","volume":"21","author":"Torp-Pedersen","year":"2000","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1345\/aph.19185","article-title":"Dofetilide: a class III-specific antiarrhythmic agent","volume":"34","author":"Kalus","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.ccep.2025.10.003_bib61","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/CIRCEP.114.002339","article-title":"Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter","volume":"8","author":"Abraham","year":"2015","journal-title":"Circulation Arrhythmia and electrophysiology"},{"issue":"7","key":"10.1016\/j.ccep.2025.10.003_bib62","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/europace\/eut407","article-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation","volume":"16","author":"Koskinas","year":"2014","journal-title":"EP Europace"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1540-8159.2011.03298.x","article-title":"The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series","volume":"35","author":"Murdock","year":"2012","journal-title":"Pacing Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.ccep.2025.10.003_bib64","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/clc.22476","article-title":"Ranolazine in cardiac arrhythmia","volume":"39","author":"Saad","year":"2016","journal-title":"Clin Cardiol"},{"issue":"12","key":"10.1016\/j.ccep.2025.10.003_bib65","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","article-title":"Vernakalant hydrochloride for rapid conversion of atrial fibrillation","volume":"117","author":"Roy","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccep.2025.10.003_bib66","first-page":"637","article-title":"A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion","volume":"4","author":"Torp-Pedersen","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccep.2025.10.003_bib67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.15420\/aer.2018.71.2","article-title":"Introducing vernakalant into clinical practice","volume":"8","author":"Hall","year":"2019","journal-title":"Arrhythm Electrophysiol Rev"}],"container-title":["Cardiac Electrophysiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918225000772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877918225000772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T20:39:47Z","timestamp":1769546387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877918225000772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1877918225000772"],"URL":"https:\/\/doi.org\/10.1016\/j.ccep.2025.10.003","relation":{},"ISSN":["1877-9182"],"issn-type":[{"value":"1877-9182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiarrhythmic Drug Therapy for Acute Management of Atrial Fibrillation and Atrial Flutter","name":"articletitle","label":"Article Title"},{"value":"Cardiac Electrophysiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccep.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}